These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 37427373)

  • 41. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Applying CRISPR-Cas9 screens to dissect hematological malignancies.
    Iyer DN; Schimmer AD; Chang H
    Blood Adv; 2023 May; 7(10):2252-2270. PubMed ID: 36355853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nuclease-Deficient Clustered Regularly Interspaced Short Palindromic Repeat-Based Approaches for
    Lek A; Ma K; Woodman KG; Lek M
    Hum Gene Ther; 2021 Mar; 32(5-6):260-274. PubMed ID: 33446040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-Cas9 for medical genetic screens: applications and future perspectives.
    Xue HY; Ji LJ; Gao AM; Liu P; He JD; Lu XJ
    J Med Genet; 2016 Feb; 53(2):91-7. PubMed ID: 26673779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-content CRISPR screening in tumor immunology.
    Holcomb EA; Pearson AN; Jungles KM; Tate A; James J; Jiang L; Huber AK; Green MD
    Front Immunol; 2022; 13():1041451. PubMed ID: 36479127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
    Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
    Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR technology for immuno-oncology applications.
    Wang J; Balan V; Marincola F
    Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR technology: The engine that drives cancer therapy.
    Zhang M; Eshraghian EA; Jammal OA; Zhang Z; Zhu X
    Biomed Pharmacother; 2021 Jan; 133():111007. PubMed ID: 33227699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The CRISPR System and Cancer Immunotherapy Biomarkers.
    Balan V; Wang J
    Methods Mol Biol; 2020; 2055():301-322. PubMed ID: 31502158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing.
    Moses C; Kaur P
    Respirology; 2019 Jul; 24(7):628-637. PubMed ID: 30883991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
    Dubrot J; Lane-Reticker SK; Kessler EA; Ayer A; Mishra G; Wolfe CH; Zimmer MD; Du PP; Mahapatra A; Ockerman KM; Davis TGR; Kohnle IC; Pope HW; Allen PM; Olander KE; Iracheta-Vellve A; Doench JG; Haining WN; Yates KB; Manguso RT
    Immunity; 2021 Mar; 54(3):571-585.e6. PubMed ID: 33497609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR/Cas gene-editing technology and its advances in dentistry.
    Chavez-Granados PA; Manisekaran R; Acosta-Torres LS; Garcia-Contreras R
    Biochimie; 2022 Mar; 194():96-107. PubMed ID: 34974144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Research Techniques Made Simple: CRISPR Genetic Screens.
    Otten ABC; Sun BK
    J Invest Dermatol; 2020 Apr; 140(4):723-728.e1. PubMed ID: 32200874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.
    Liu W; Li L; Jiang J; Wu M; Lin P
    Precis Clin Med; 2021 Sep; 4(3):179-191. PubMed ID: 34541453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity.
    Wang YM; Wang HZ; Jian YZ; Luo ZT; Shao HW; Zhang WF
    Hum Gene Ther; 2022 Apr; 33(7-8):358-370. PubMed ID: 34963339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [CRISPR/Cas-based genome editing in Aspergillus niger].
    Zheng X; Zheng P; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2021 Mar; 37(3):980-990. PubMed ID: 33783162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.